Recital 106, Decision_act (EU) 2018/9019

In forcesince 29 Oct 2018

Second, the Notifying Party refers to an analogous situation in the United States,

in order to argue that no competition concerns should arise. In particular, Mars notes that it already owns veterinary clinics in the United States where […].

Further, sales data indicates that […]. Mars argues that it intends to apply the same strategy in Europe, through its acquisition of AniCura.

119 Form CO, paragraph 297.

120 Form CO, paragraph 29; Parties' response to RFI 7, question 3(b).

121 Form CO, paragraph 300.

122 Parties' response to RFI 7, question 3(b).

123 Parties' response to RFI 7, question 3(b). during the course of the market investigation, the Commission notes that in Denmark, the main four competitors (Hill's, Dechra, Spectrum and Virbac) sold between one third and two thirds of their total sales in Denmark through AniCura and VetFamily.125